N-ethyl-N-(4-fluorophenyl)biguanide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-ethyl-N-(4-fluorophenyl)biguanide
• 英文别名: N-ethyl-4-florophenyl biguamide；3-(Diaminomethylidene)-1-ethyl-1-(4-fluorophenyl)guanidine；3-(diaminomethylidene)-1-ethyl-1-(4-fluorophenyl)guanidine
• 化学式: C₁₀H₁₄FN₅
• 分子量: 223.253
• InChiKey: MODIVLJYWHBWQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  91.5
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-乙基-4-氟苯胺 、 二聚氰胺 以 乙腈 为溶剂， 反应 1.0h， 生成 N-ethyl-N-(4-fluorophenyl)biguanide
  参考文献：
  名称：

  면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도

  摘要：

  本发明涉及一种新的化合物及其用途，可有效预防和治疗免疫性疾病。该新化合物抑制炎症性细胞因子的生成，增强调节T细胞的活性，具有免疫调节功能，同时抑制自身抗体的产生，可以控制过度的免疫反应，并具有抑制巨噬细胞分化的效果，可用于治疗各种免疫性疾病，如自身免疫性疾病、炎症性疾病和移植排斥疾病等由免疫反应失调引起的疾病。

  公开号：

  KR20150124880A

文献信息

• COMPOSITION FOR PREVENTING AND TREATING TRANSPLANT REJECTION OR TRANSPLANT REJECTION DISEASES, COMPRISING NOVEL COMPOUND AND CALCINEURIN INHIBITOR
  申请人：The Catholic University Of Korea Industry-Academic Cooperation Foundation

  公开号：EP3878443A1

  公开（公告）日：2021-09-15

  The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone. Thus, the present invention may be used in the field of pharmaceutics relating to transplantation rejection or various immune disorders possibly occurring after transplantation.

  本发明涉及一种用于预防或治疗移植排斥反应或移植排斥疾病的组合物，该组合物由一种新型化合物和一种钙调素抑制剂组成。本发明的联合给药1）降低致病性 Th1 细胞或 Th17 细胞的活性；2）增加 Treg 细胞的活性；3）对单独给药时出现的副作用（如组织损伤）具有抑制作用；4）抑制各种致病途径；5）抑制炎症细胞的细胞死亡；6）增加线粒体的活性、6）在体内或体外异基因模型、移植排斥疾病模型、皮肤移植模型和肝移植患者中提高线粒体的活性，从而在抑制移植排斥反应的同时减轻单独使用传统免疫抑制剂可能产生的副作用。因此，本发明可用于与移植排斥或移植后可能出现的各种免疫紊乱有关的制药领域。
• Compound having immune disease treatment effect and use thereof
  申请人：THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY—ACADEMIC COOPERATION FOUNDATION

  公开号：US10100006B2

  公开（公告）日：2018-10-16

  Provided is a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present subject matter has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.

  本发明提供了一种能够有效预防和治疗免疫疾病的新型化合物及其用途。本发明的新型化合物具有抑制炎症细胞因子的产生、提高具有免疫调节功能的调节性 T 细胞的活性、抑制自身抗体的产生以调节过度的免疫反应、抑制破骨细胞的分化等作用，因此可用于治疗因各种免疫反应调节异常而导致的自身免疫性疾病、炎症性疾病和移植排斥性疾病等免疫性疾病。
• COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF
  申请人：The Catholic University Of Korea Industry-Academic

  公开号：EP3130582B1

  公开（公告）日：2018-10-10
• NOVEL COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF
  申请人：THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

  公开号：US20170114008A1

  公开（公告）日：2017-04-27

  The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response
• 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
  申请人：THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION 가톨릭대학교 산학협력단(220050224041) BRN ▼114-82-07929

  公开号：KR20150124880A

  公开（公告）日：2015-11-06

  본 발명은 면역질환을 효과적으로 예방 및 치료할 수 있는 신규 화합물 및 이의 용도에 관한 것이다. 본 발명의 신규 화합물은 염증성 사이토카인의 생성을 억제시키며, 면역조절 기능을 갖는 조절 T 세포의 활성을 증대시킬 뿐만 아니라, 자가 항체 생산을 억제하여 과도한 면역반응을 제어할 수 있으며 파골세포의 분화를 억제할 수 있는 효과가 있어, 각종 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환 치료를 위한 용도로 사용될 수 있는 효과가 있다.

  本发明涉及一种新的化合物及其用途，可有效预防和治疗免疫性疾病。该新化合物抑制炎症性细胞因子的生成，增强调节T细胞的活性，具有免疫调节功能，同时抑制自身抗体的产生，可以控制过度的免疫反应，并具有抑制巨噬细胞分化的效果，可用于治疗各种免疫性疾病，如自身免疫性疾病、炎症性疾病和移植排斥疾病等由免疫反应失调引起的疾病。